Levofloxacin IV, Oral | Right Decisions

Right Decisions
Antimicrobial prescribing: NHS Grampian, Orkney & Shetland
Back
Protected (Alert) Policy
Levofloxacin IV, Oral

Announcements and latest updates

Polyfill.io vulnerability

28 june 2024

Our eHealth team advised us yesterday of an international vulnerability relating to polyfill.io . This domain has become compromised and is spreading malware through a widespread supply chain attack, estimated to affect over 110,000 websites including major websites such as the BBC. The Polyfill site offered widely used bits of code for older browsers that allowed the use of modern Javascript features. Such code makes the work for web developers easier and allows compatibility with a broader range of browsers.

Websites that have used the Javascript code from Polyfill have been urged to remove such code immediately. The change occurred after a suspected Chinese firm purchased the domain in early 2024.

Tactuum have identified and are now testing a fix to remove all Polyfill code from the RDS site.. They will be deploying the fix on Monday 1 July along with other planned fixes and amendments. I will notify you of the timing of the deployment as soon as possible.

In the meantime, please ensure that you have up-to-date anti-virus software installed on your machines and personal devices.

Permitted indications

May be used for the following indication:

Second-line in accordance with guidelines for severe pneumonia in hospitalised patients where there is proven penicillin or macrolide resistance or allergy.

Only on the advice of a Cystic Fibrosis Specialist for:

Infective exacerbations in cystic fibrosis patients where the organism is sensitive to levofloxacin.

For all other indications, contact the duty Medical Microbiologist.

Not licensed for use in children.